Similar gene expression signatures and similar benefits from menin inhibition have been shown in preclinical studies for NPM1-mutant AML [154,155], NUP98-rearranged AML [156], and UBTF mutated AML [157,158]. The gene discussed is MEN1; the disease is acute myeloid leukemia.